- Market Capitalization, $K 1,044,235
- Shares Outstanding, K 89,788
- Annual Sales, $ 0 K
- Annual Income, $ -273,550 K
- 60-Month Beta 2.11
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-1.99 (-14.34%)since 01/17/20
| || |
-1.03 (-7.97%)since 11/19/19
| || |
-9.35 (-44.02%)since 02/19/19
- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020
-- Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant's CEO, will present...
-- Hiroshi Nomura, President, CEO, and Representative Director of Sumitomo Dainippon Pharma and Adele Gulfo, Chief Business and Commercial Development Officer of Sumitovant Biopharma, appointed to Board...
Sumitovant Biopharma Ltd. was today unveiled as a new, global biopharmaceutical company through the closing of the transaction previously announced on October 31, 2019 between Sumitomo Dainippon Pharma...
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant's President and CEO,...
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
It appears that the reign of the opioid drugs in the global pain management markets could be coming to an end. While opioids have long been the 'best' choice to address the pain patients suffer from various...